{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:37:17Z","timestamp":1759333037875},"reference-count":20,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.jns.2006.04.011","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T07:39:32Z","timestamp":1179992372000},"page":"50-52","source":"Crossref","is-referenced-by-count":24,"title":["\u201cThinking without thinking\u201d about natalizumab and PML"],"prefix":"10.1016","volume":"259","author":[{"given":"Richard M.","family":"Ransohoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jns.2006.04.011_bib1","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/nn1005-1275","article-title":"Natalizumab and PML","volume":"8","author":"Ransohoff","year":"2005","journal-title":"Nat Neurosci"},{"issue":"7","key":"10.1016\/j.jns.2006.04.011_bib2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nn0705-837","article-title":"Multiple sclerosis woes","volume":"8","year":"2005","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jns.2006.04.011_bib3","series-title":"Blink","author":"Gladwell","year":"2005"},{"key":"10.1016\/j.jns.2006.04.011_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMe058122","article-title":"Progressive multifocal leukoencephalopathy and natalizumab\u2014unforeseen consequences","author":"Berger","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jns.2006.04.011_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrd1752","article-title":"Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab","volume":"4","author":"Steinman","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.jns.2006.04.011_bib6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0092-8674(00)81301-X","article-title":"Differential requirements for alpha4 integrins during fetal and adult hematopoiesis","volume":"85","author":"Arroyo","year":"1996","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.jns.2006.04.011_bib7","doi-asserted-by":"crossref","first-page":"9349","DOI":"10.1128\/MCB.23.24.9349-9360.2003","article-title":"Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing","volume":"23","author":"Scott","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jns.2006.04.011_bib8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.3161.3161","article-title":"Hierarchy of molecular pathway usage in bone marrow homing and its shift by cytokines","author":"Bonig","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jns.2006.04.011_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0301-472X(00)00668-8","article-title":"Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic progenitor cells","volume":"29","author":"Hidalgo","year":"2001","journal-title":"Exp Hematol"},{"issue":"6","key":"10.1016\/j.jns.2006.04.011_bib10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1084\/jem.193.6.741","article-title":"Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow","volume":"193","author":"Koni","year":"2001","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.jns.2006.04.011_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJM198802043180507","article-title":"Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy","volume":"318","author":"Houff","year":"1988","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jns.2006.04.011_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/jlb.65.4.428","article-title":"Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS","volume":"65","author":"Jensen","year":"1999","journal-title":"J Leukoc Biol"},{"issue":"Suppl 2","key":"10.1016\/j.jns.2006.04.011_bib13","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1086\/344280","article-title":"Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy","volume":"186","author":"Sabath","year":"2002","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.jns.2006.04.011_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nri1130","article-title":"Three or more routes for leukocyte migration into the central nervous system","volume":"3","author":"Ransohoff","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.jns.2006.04.011_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.it.2005.07.004","article-title":"The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms","volume":"26","author":"Engelhardt","year":"2005","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jns.2006.04.011_bib16","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"Stuve","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2006.04.011_bib17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis","volume":"63","author":"Stuve","year":"2006","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.jns.2006.04.011_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ncl.2004.09.005","article-title":"Natalizumab and other monoclonal antibodies","volume":"23","author":"Ursell","year":"2005","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jns.2006.04.011_bib19","series-title":"The Perfect Storm","author":"Junger","year":"1997"},{"key":"10.1016\/j.jns.2006.04.011_bib20","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","author":"Van Assche","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X07001529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X07001529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T08:31:17Z","timestamp":1587544277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X07001529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":20,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0022510X07001529"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2006.04.011","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}